These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33837219)

  • 21. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution.
    Qi H; Ma ML; Jiang HW; Ling JY; Chen LY; Zhang HN; Lai DY; Li Y; Guo ZW; Hu CS; Guo SJ; Meng QF; Ren Y; Yang X; Wang W; Zhou J; Zhao XD; Li H; Tao SC
    Cell Mol Immunol; 2021 Apr; 18(4):1067-1069. PubMed ID: 33664486
    [No Abstract]   [Full Text] [Related]  

  • 23. Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4
    Pušnik J; Richter E; Schulte B; Dolscheid-Pommerich R; Bode C; Putensen C; Hartmann G; Alter G; Streeck H
    Cell Rep; 2021 Jun; 35(13):109320. PubMed ID: 34146478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.
    Koerber N; Priller A; Yazici S; Bauer T; Cheng CC; Mijočević H; Wintersteller H; Jeske S; Vogel E; Feuerherd M; Tinnefeld K; Winter C; Ruland J; Gerhard M; Haller B; Christa C; Zelger O; Roggendorf H; Halle M; Erber J; Lingor P; Keppler O; Zehn D; Protzer U; Knolle PA
    Nat Commun; 2022 Jan; 13(1):153. PubMed ID: 35013191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19.
    Wu J; Liang B; Chen C; Wang H; Fang Y; Shen S; Yang X; Wang B; Chen L; Chen Q; Wu Y; Liu J; Yang X; Li W; Zhu B; Zhou W; Wang H; Li S; Lu S; Liu D; Li H; Krawczyk A; Lu M; Yang D; Deng F; Dittmer U; Trilling M; Zheng X
    Nat Commun; 2021 Mar; 12(1):1813. PubMed ID: 33753738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19.
    Jörrißen P; Schütz P; Weiand M; Vollenberg R; Schrempf IM; Ochs K; Frömmel C; Tepasse PR; Schmidt H; Zibert A
    Front Immunol; 2021; 12():679841. PubMed ID: 34421894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.
    Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V
    PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
    Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological imprint of COVID-19 on human peripheral blood leukocyte populations.
    Kratzer B; Trapin D; Ettel P; Körmöczi U; Rottal A; Tuppy F; Feichter M; Gattinger P; Borochova K; Dorofeeva Y; Tulaeva I; Weber M; Grabmeier-Pfistershammer K; Tauber PA; Gerdov M; Mühl B; Perkmann T; Fae I; Wenda S; Führer H; Henning R; Valenta R; Pickl WF
    Allergy; 2021 Mar; 76(3):751-765. PubMed ID: 33128792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay.
    McDade TW; McNally EM; Zelikovich AS; D'Aquila R; Mustanski B; Miller A; Vaught LA; Reiser NL; Bogdanovic E; Fallon KS; Demonbreun AR
    PLoS One; 2020; 15(8):e0237833. PubMed ID: 32797108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
    Mveang Nzoghe A; Leboueny M; Kuissi Kamgaing E; Maloupazoa Siawaya AC; Bongho EC; Mvoundza Ndjindji O; Padzys GS; Ndeboko B; Ategbo S; Djoba Siawaya JF
    BMC Res Notes; 2021 Apr; 14(1):152. PubMed ID: 33879229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
    Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
    Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1.
    Pagano S; Yerly S; Meyer B; Juillard C; Suh N; Le Terrier C; Daguer JP; Farrera-Soler L; Barluenga S; Piumatti G; Hartley O; Lemaitre B; Eberhardt CS; Siegrist CA; Eckerle I; Stringhini S; Guessous I; Kaiser L; Pugin J; Winssinger N; Vuilleumier N
    Eur J Clin Invest; 2021 Nov; 51(11):e13661. PubMed ID: 34324704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of toll-like receptor agonists and SARS-CoV-2 antigens on interferon (IFN) expression by peripheral blood CD3
    Abdolmohammadi-Vahid S; Baradaran B; Sadeghi A; Bezemer GFG; Kiaee F; Adcock IM; Folkerts G; Garssen J; Mortaz E
    Exp Mol Pathol; 2024 Jun; 137():104897. PubMed ID: 38691979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.
    Zedan HT; Nasrallah GK
    EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435
    [No Abstract]   [Full Text] [Related]  

  • 38. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.
    Saletti G; Gerlach T; Jansen JM; Molle A; Elbahesh H; Ludlow M; Li W; Bosch BJ; Osterhaus ADME; Rimmelzwaan GF
    Sci Rep; 2020 Dec; 10(1):21447. PubMed ID: 33293664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4
    Taborska P; Strizova Z; Stakheev D; Sojka L; Bartunkova J; Smrz D
    Front Immunol; 2021; 12():629102. PubMed ID: 34012431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional responsiveness of memory T cells from COVID-19 patients.
    Tavukcuoglu E; Horzum U; Cagkan Inkaya A; Unal S; Esendagli G
    Cell Immunol; 2021 Jul; 365():104363. PubMed ID: 33905951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.